{
    "Trade/Device Name(s)": [
        "LZI Tramadol Enzyme Immunoassay"
    ],
    "Submitter Information": "Lin-Zhi International, Inc.",
    "510(k) Number": "K201223",
    "Predicate Device Reference 510(k) Number(s)": [
        "K182280"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "June 4, 2020",
    "Summary Letter Received Date": "May 6, 2020",
    "Submission Date": "May 4, 2020",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Tramadol"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Beckman Coulter AU480 Analyzer",
        "Automated clinical chemistry analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay",
        "Enzyme immunoassay (EIA)"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for LZI Tramadol Enzyme Immunoassay for qualitative and semi-quantitative detection of tramadol in human urine using automated clinical chemistry analyzers",
    "Indications for Use Summary": "For the qualitative and semi-quantitative determination of tramadol in human urine at a cutoff of 100 ng/mL on automated clinical chemistry analyzers; provides preliminary analytical results requiring confirmation by a more specific method such as GC/MS or LC/MS.",
    "fda_folder": "Toxicology"
}